| Trial Title | Who can participate? | Where is the trial open? | What question is the trial asking? | Full trial information |
|---|---|---|---|---|
CTRIAL 22-17 NRG GU012 SAMURAI Renal |
Adults (18+) with a kidney (renal cell) cancer which has spread beyond the kidneys. They must be suitable to receive standard of care immunotherapy and they can have started the immunotherapy up to 90 days before starting the trial radiotherapy. |
|
This study is testing whether adding stereotactic ablative radiotherapy (SABR), a very precise, high-dose form of radiation, to the main kidney tumor, along with immunotherapy, can help people with kidney cancer that has spread (metastatic renal cell carcinoma) do better than with immunotherapy alone. The tumors have not been removed with surgery. The main thing the study is measuring is how long patients can go without the cancer getting worse on scans and without needing surgery to remove the kidney. |
